<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9894">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05687981</url>
  </required_header>
  <id_info>
    <org_study_id>(IIIH) &amp;(IINB) in pain control</org_study_id>
    <nct_id>NCT05687981</nct_id>
  </id_info>
  <brief_title>The Analgesic Efficacy of Two Bupivacaine Concentrations for Combined Ilioinguinal and Iliohypogastric Nerve Block in Postherniorrhaphy Pain</brief_title>
  <official_title>The Analgesic Efficacy of Two Bupivacaine Concentrations for Combined Ilioinguinal and Iliohypogastric Nerve Block in Postherniorrhaphy Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will be undertaken to compare the postoperative analgesic effect of 0.25%&#xD;
      bupivacaine and 0.5% bupivacaine for unilateral ilioinguinal and Iliohypogastric nerve block&#xD;
      after open inguinal hernia repair.&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      The time to first request for rescue analgesia.&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
        1. The post-operative pain in the form of NRS scores at rest &amp; during movement at 0, 2, 4,&#xD;
           8, 12, 18 and 24 hours post-procedure.&#xD;
&#xD;
        2. The total 24 hour opioid consumption.&#xD;
&#xD;
        3. The incidence of complication related to nerve block (urinary retention, hematoma,&#xD;
           hypotension and arrhythmia).&#xD;
&#xD;
        4. Patient satisfaction&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative pain is a common complication that may cause a neuroendocrine stress response,&#xD;
      which is characterized by increased release of catabolic and immunosuppressive pituitary&#xD;
      hormones and activation of the sympathetic nervous system. Excessive postoperative pain and&#xD;
      the physiological stress response can influence postoperative outcomes, length of hospital&#xD;
      stay and overall costs of hospital care Inguinal herniorrhaphy is a common outpatient&#xD;
      surgical procedure with approximately 20 million operations performed worldwide annually.&#xD;
&#xD;
      Patients undergoing this procedure often experience moderate-to-severe pain, which can hinder&#xD;
      post anesthesia care unit (PACU) discharge. While pain can be treated with opioid therapy,&#xD;
      the literature supports that opioids may cause postoperative nausea, vomiting, hypoxia, and&#xD;
      urinary retention. In contrast, analgesia provided by regional block has been shown to&#xD;
      decrease the previous complications.&#xD;
&#xD;
      There is an ongoing interest in developing regional anesthetic techniques that may reduce or&#xD;
      eliminate the use of opioid analgesics after minor surgical procedures such as hernia repair.&#xD;
&#xD;
      Regional analgesia has found wide acceptance both by the patients and their treating&#xD;
      physicians, and therefore, it is now an important part of multimodal analgesia techniques.&#xD;
      Ilioinguinal/iliohypogastric nerve block(IINB),transversus abdominis plane (TAP) block,&#xD;
      paravertebral and rectus sheath, have all been used for providing analgesia following&#xD;
      abdominal surgeries .&#xD;
&#xD;
      The combined ilioinguinal and iliohypogastric nerve block (IINB) is a commonly used technique&#xD;
      for blockade of the ilioinguinal/iliohypogastric (IIIH) nerves and has been shown to decrease&#xD;
      pain after OIH as well as reduce opioid requirements.&#xD;
&#xD;
      Bupivacaine belongs to the amide family, and its structure is similar to that of lidocaine.&#xD;
      Bupivacaine is a potent agent capable of producing prolonged anesthesia. Its long duration of&#xD;
      action plus its tendency to provide more sensory than motor block has made it a popular drug&#xD;
      for providing prolonged analgesia during the postoperative period.&#xD;
&#xD;
      We assume that the use of higher concentration of bupivacaine in ilioinguinal and&#xD;
      iliohypogastric nerve block (IINB) might increase the efficacy of post-operative analgesia&#xD;
      and patient satisfaction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2023</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to first request for rescue analgesia.</measure>
    <time_frame>24 hours</time_frame>
    <description>if score is â‰¥ 3 analgesia needed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The post-operative pain in the form of NRS.</measure>
    <time_frame>at 0, 2, 4, 8, 12, 18 and 24 hours post-procedure.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total 24 hour opioid consumption</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of complication related to nerve block</measure>
    <time_frame>48 hours</time_frame>
    <description>urinary retention, hematoma, hypotension and arrhythmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>48 hours</time_frame>
    <description>in the form of 4 point satisfaction questionnaire: where 1 would be satisfied, 2=neutral, 3=dissatisfied, and 4=extremely dissatisfied.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hernia, Inguinal</condition>
  <arm_group>
    <arm_group_label>Patients will receive 10 ml of 0.5% bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 2mg dexamethasone will be added</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients will receive 10 ml of 0.25% bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 2mg dexamethasone will be added</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>the use of higher concentration of bupivacaine in ilioinguinal and iliohypogastric nerve block (IINB) might increase the efficacy of postoperative analgesia</description>
    <arm_group_label>Patients will receive 10 ml of 0.5% bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>2 mg dexamethasone</description>
    <arm_group_label>Patients will receive 10 ml of 0.25% bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 21 and 60 years age with the American Society of Anesthesiologists'&#xD;
             status I or II scheduled for elective primary open inguinal hernia repair&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient refusal.&#xD;
&#xD;
          2. Body mass index (BMI) &gt;40 kg m2.&#xD;
&#xD;
          3. The presence of skin infection at the injection site.&#xD;
&#xD;
          4. Allergy to local anesthetic drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad Abduallah</last_name>
    <role>Study Director</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariam Elkasass</last_name>
    <phone>00201024234668</phone>
    <email>mariam160758_pg@med.tanta.ed</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alaa Abohager</last_name>
    <phone>00201099220281</phone>
  </overall_contact_backup>
  <reference>
    <citation>Bugedo GJ, Carcamo CR, Mertens RA, Dagnino JA, Munoz HR. Preoperative percutaneous ilioinguinal and iliohypogastric nerve block with 0.5% bupivacaine for post-herniorrhaphy pain management in adults. Reg Anesth. 1990 May-Jun;15(3):130-3.</citation>
    <PMID>2265166</PMID>
  </reference>
  <reference>
    <citation>Kamal K, Jain P, Bansal T, Ahlawat G. A comparative study to evaluate ultrasound-guided transversus abdominis plane block versus ilioinguinal iliohypogastric nerve block for post-operative analgesia in adult patients undergoing inguinal hernia repair. Indian J Anaesth. 2018 Apr;62(4):292-297. doi: 10.4103/ija.IJA_548_17.</citation>
    <PMID>29720755</PMID>
  </reference>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 9, 2023</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>January 17, 2023</last_update_submitted>
  <last_update_submitted_qc>January 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Mariam Jamal Elkasass</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>nerve block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

